DIADIA0.73%
SPYSPY0.54%
QQQQQQ0.59%
Trending
Top trending tickerCROCRO2.45%
DJIADJIA0.36%
DIADIA0.73%
TGTTGT1.95%
CIFRCIFR8.26%
OPEAZZXOPEAZZX0.41%
AVAXAVAX0.23%
GSITGSIT0.50%
CRCLCRCL5.80%
FTNTFTNT0.85%
Top trending tickerCROCRO2.45%
DJIADJIA0.36%
DIADIA0.73%
TGTTGT1.95%
CIFRCIFR8.26%
OPEAZZXOPEAZZX0.41%
AVAXAVAX0.23%
GSITGSIT0.50%
CRCLCRCL5.80%
FTNTFTNT0.85%
homeSymbolSTVNnews
STVN logo

STVNStevanato Group Spa

$17.08
$0.21
(1.22%)
Today
Closed $17.08
$0.00
(0.00%)
After Hours
Updated: 04:10 PM EDT
EarningsAug 4
Mkt Cap$4.66B
Vol538,533.00
50

Neutral Sentiment

How do you feel about STVN?

Feed

News

Sentiment

Earnings

Fundamentals

Info

News
all
press releases
Is Stevanato Group S.p.A. (STVN) A Good Stock To Buy Now?
Is Stevanato Group S.p.A. (STVN) A Good Stock To Buy Now...
Yahoo! Finance: News
News Placeholder
More News
News Placeholder
Stevanato Group Introduces Deora, a Pen Injector for Subcutaneous Delivery in Diabetes and Weight Management
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions for the pharmaceutical, biotechnology, and life sciences industries, today introduced Deora, a new proprietary pen injector platform targeting incretin-based therapies, as...
Business Wire
News Placeholder
Stevanato Group Announces Results of Ordinary and Extraordinary Shareholders Meeting
Stevanato Group S.p.A. (NYSE: STVN) (the Company), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced that all resolutions proposed to the shareholders at the Ordinary and...
Business Wire
News Placeholder
Implied Volatility Surging for Stevanato Stock Options
Investors need to pay close attention to STVN stock based on the movements in the options market lately.
Zacks
News Placeholder
Stevanato Group (STVN) Q1 Earnings and Revenues Beat Estimates
Stevanato (STVN) delivered earnings and revenue surprises of +6.56% and +2.32%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Stevanato Group Delivers 7% Revenue Growth (10% at Constant Currency) for the First Quarter of Fiscal 2026
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today...
Business Wire
News Placeholder
Madrigal (MDGL) Reports Q1 Loss, Beats Revenue Estimates
Madrigal (MDGL) delivered earnings and revenue surprises of +9.97% and +3.38%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Stevanato Group to Participate in Three Upcoming Investor Conferences
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in three upcoming investor conferences: Tuesday, May 12, at 8:00...
Business Wire
News Placeholder
Analysts Estimate Harrow (HROW) to Report a Decline in Earnings: What to Look Out for
Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
News Placeholder
Stevanato Group S.p.A. (NYSE:STVN) Given Average Recommendation of "Hold" by Brokerages
Shares of Stevanato Group S.p.A. (NYSE:STVN - Get Free Report) have been assigned an average rating of "Hold" from the five ratings firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.

Advertisement|Remove ads.